IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS

BACKGROUND: The lack of appropriate preclinical murine glioblastoma models limits comprehensive toxicity/efficacy evaluation of investigational agents. To overcome this challenge, we evaluated the safety and activity of a new immunotherapeutic technology that we have pioneered (composed of tumor mRN...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Carrera-Justiz, Sheila, Stover, Brian, Milner, Rowan, Weidert, Frances, Huang, Jianping, Mitchell, Duane, Mendez-Gomez, Hector, Sayour, Elias
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847721/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.539
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars